Merck's gefapixant successful in late-stage chronic cough studies

Following up on its initial announcement in March, Merck (NYSE:MRK) announces positive detailed results from two Phase 3 clinical trials, COUGH-1 and COUGH-2, evaluating gafapixant in adult patients with refractory or unexplained chronic cough.